Malaria continues to be one of the most common infections, with 247 million cases worldwide resulting in more than 619,000 deaths yearly. Children and pregnant women are the populations most vulnerable to this sickness . The first-line antimalarial drugs now in use continue to be ineffective against Plasmodium falciparum, the most dangerous malaria parasite . International researchers are always seeking novel approaches to combat the new parasite strain. The discovery and development of novel antimalarial medications over the past several years has enhanced awareness of the need to eradicate and prevent malaria . The papain-family cysteine proteases falcipain-2 (FP-2) and falcipain-3 (FP-3) are known to catalyze the proteolysis of host hemoglobin in Plasmodium falciparum, a step required for the development of erythrocytic parasites .